RightFit
RecruitingPhase not listed

A Novel Approach Utilizing Organ Specific Age Proteomics

Investigating Cellular Senescence and Organ Aging in Breast Cancer Patients Undergoing Adjuvant Chemotherapy: A Novel Approach Utilizing Organ Specific Age Proteomics

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
22 Years to 66 Years
Sex
Female only
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study looks at signs of aging in the blood before and after chemotherapy in women with early-stage breast cancer. It tests whether aging in immune cells, which help fight infections, reflects aging in different organs.

This study compares changes in P16INK4A expression and plasma proteomic signatures of specific organ age pre- and post-chemotherapy in women treated with adjuvant chemotherapy for early-stage breast cancer. It aims to determine if biological and accelerated immune aging, assessed using T cells from peripheral blood, represents aging in different organs. Patients receiving chemotherapy, especially adjuvant regimens that include anthracyclines and taxanes, often experience late development of cardiac toxicity, functional loss, and cognitive decline. Comparing baseline characteristics with organ aging before therapy might identify patients at the highest risk for chemotherapy complications. For example, this is clinically significant for patients whose therapy includes taxanes or other drugs known to cause peripheral neuropathy. Identifying aging in the neurological or vascular systems before treatment might lead to changes in regimens. Determining accelerated aging in specific organs allows for investigating interventions to mitigate organ damage. For instance, identifying patients at the highest risk of cardiac aging after treatment could lead to testing the effects of exercise, senolytics, and other strategies to reduce the risk of long-term heart disease.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Be age 22 to 65.
  • Have early-stage breast cancer (stage I, II, or III).
  • Be able to understand and read English.
  • Get care at the study site.
  • Be able to understand and take part in study activities for the whole study.

Who can't join

  • Be unable to give consent, meaning agree to join the study.
  • Be unable to communicate by speaking.
  • Be unable to understand or read English.
  • Be in hospice care, which focuses on comfort near the end of life.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Age ≥22years and \<66 years * Diagnosed with early-stage breast cancer (The American Joint Committee on Cancer stages I-III). * Understand and read English. * Receive care at the study site. * Able to understand and participate in study procedures for length of study. Exclusion Criteria: * Unable to provide consent, unable to communicate verbally. * Unable to understand or read English. * Enrolled in hospice care.

Study sites (1)

NC